<DOC>
	<DOCNO>NCT01818752</DOCNO>
	<brief_summary>This Phase 3 multicenter , open-label , randomized study transplant-ineligible subject newly diagnose multiple myeloma . Subjects randomize receive 1 2 treatment regimen : Carfilzomib , Melphalan Prednisone ( CMP ) Velcade® ( Bortezomib ) , Melphalan Prednisone ( VMP ) .</brief_summary>
	<brief_title>Phase 3 Study Carfilzomib , Melphalan , Prednisone v Bortezomib , Melphalan , Prednisone Newly Diagnosed Multiple Myeloma ( CLARION )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Newly diagnose symptomatic multiple myeloma Transplantineligibility Males females ≥ 18 year age Left ventricular ejection fraction ( LVEF ) ≥ 40 % Waldenstrom macroglobulinemia Known amyloidosis Plasma cell leukemia POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein skin change ) Significant neuropathy ( Grades ≥ 2 ) within 14 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>